Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Five Below Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q4, Five Below (NASDAQ:FIVE) earned $140.20 million, a 479.87% increase from the preceding quarter. Five Below also posted a total of $996.33 million in sales, a 63.97% increase since Q3.

Benzinga

Why Longeveron Shares Are Surging Today

Longeveron Inc (NASDAQ: LGVN) shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's disease in "Alzheimer's & Dementia: The Journal of the Alzheimer's Association."

Benzinga

Arhaus Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data Arhaus (NASDAQ:ARHS) posted a 55.84% decrease in earnings from Q3. Sales, however, increased by 17.16% over the previous quarter to $238.23 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Agile Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Agile Therapeutics (NASDAQ:AGRX) reported Q4 sales of $1.51 million. Earnings fell to a loss of $23.36 million, resulting in a 39.26% decrease from last quarter.

Benzinga

Motus GI Hldgs's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Motus GI Hldgs's (NASDAQ:MOTS) reported sales totaled $99.00 thousand. Despite a 0.12% increase in earnings, the company posted a loss of $4.82 million.

Benzinga

vTv Therapeutics's Return On Capital Employed Overview

vTv Therapeutics (NASDAQ:VTVT) brought in sales totaling $9.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 547.3%, resulting in a loss of $9.48 million.

Benzinga

Here's How This Bitcoin Mining Company Fared In FY21

Bitcoin mining company Sphere 3D Corp (NASDAQ:ANY) reported an FY21 revenue decline of 23.3% year-on-year to $3.72 million. The gross margin contracted 80 bps to 45.6%. Operating expenses more than doubled to $21.4 million. EPS loss was $(0.58) versus $(0.98) last year. Sphere 3D held $54.4 million in cash and equivalents. CEO Peter Tassiopoulos…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Celsion: Q4 Earnings Insights

Celsion (NASDAQ:CLSN) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Bassett Furniture Q1 Earnings

Bassett Furniture Indus (NASDAQ:BSET) reported its Q1 earnings results on Thursday, March 31, 2022 at 09:00 AM. Here's what investors need to know about the announcement.

Benzinga

Galectin Therapeutics: Q4 Earnings Insights

Galectin Therapeutics (NASDAQ:GALT) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Acacia Research Stock Gains On Record Q4 Results, New Buyback

Acacia Research Corp (NASDAQ:ACTG) reported fourth-quarter revenues of $63.3 million compared to $4.4 million in 4Q20. The company's Intellectual Property business generated $51.3 million in licensing and other revenue versus $4.4 million last year. Operating income recovered to $31.3 million from a loss of $(6.4) million a year ago. EPS was $0.45 compared…

Benzinga

Baidu, iQIYI Explore Options After US SEC Added Them To Provisional List Pending Audit Review

Baidu Inc (NASDAQ:BIDU) explored options after the U.S. SEC added the Chinese search engine giant to a list of companies that faced delisting concerns, Reuters reports. Beijing refused to permit U.S. officials to review their auditors' work, Bloomberg reports. A 2020 U.S. law mandated a three-year clock for firms to comply with inspection…

Benzinga

Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status

Clovis Oncology Inc (NASDAQ:CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer. Rubraca achieved the primary endpoint of significantly improved progression-free survival (PFS) compared with placebo (20.2 months vs. 9.2 months). The median PFS for the HRD-positive patient…

Benzinga

Expert Ratings For JB Hunt Transport Servs

JB Hunt Transport Servs (NASDAQ:JBHT) has observed the following analyst ratings within the last quarter:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

How Is The Market Feeling About Google - Class C Capital Stock?

Alphabet Inc - Class C Capital Stock's (NASDAQ:GOOG) short percent of float has risen 4.92% since its last report. The company recently reported that it has 1.77 million shares sold short, which is 0.64% of all regular shares that are available for trading.

Benzinga

Analyzing Microsoft Corporation's Short Interest

Microsoft Corporation's (NASDAQ:MSFT) short percent of float has risen 16.67% since its last report. The company recently reported that it has 41.49 million shares sold short, which is 0.56% of all regular shares that are available for trading.

Benzinga

Why Clovis Oncology Stock Is Soaring Today

Clovis Oncology Inc (NASDAQ: CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with the placebo.

Benzinga

Jim Cramer Shares His Thoughts On Crocs, Hertz Global And More

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Olin Corporation’s (NYSE: OLN) pricing is not going to hold up. He warned investors to remain careful with the stock.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Key Takeaways From Barclays' AMD Downgrade

Barclays analyst Blayne Curtis downgraded Advanced Micro Devices Inc (NASDAQ:AMD) to Equal Weight from Overweight with a price target of $115, down from $148 (3.54% downside). The company's growth story needs a pause with cyclical risks looming in 2023, admitted Curtis. AMD remains positioned to gain market share in both the client and server markets…

Benzinga

Recap: Taysha Gene Therapies Q4 Earnings

Taysha Gene Therapies (NASDAQ:TSHA) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Renalytix: Q2 Earnings Insights

Renalytix (NASDAQ:RNLX) reported its Q2 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

PDS Biotechnology: Q4 Earnings Insights

PDS Biotechnology (NASDAQ:PDSB) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Dare Bioscience Q4 Earnings

Dare Bioscience (NASDAQ:DARE) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Nano X Imaging Q4 Earnings

Nano X Imaging (NASDAQ:NNOX) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Eloxx Pharmaceuticals Q4 Earnings

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

1 … 750 751 752 753

People

Jim Cramer

506 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.